November 17, 2015

FDA approves Darzalex for patients with previously treated multiple myeloma

Today the U.S. Food and Drug Administration granted accelerated approval for Darzalex (daratumumab) to treat patients with multiple myeloma who have received at least three prior treatments. Darzalex is the first monoclonal antibody approved for treating multiple myeloma. Read more here:  

October 15, 2015

Guess the Diagnosis with Frits van Rhee, MD, PhD

Guess the Diagnosis: Case 1 Watch the video segments Case-Based Peer Perspectives on Targeted Oncology  Lisa B. is a 47-year-old female store owner from St. Louis, with a 10-month history of fatigue, night sweats, and weight loss. She presents to her PCP with generalized lymphadenopathy, most prominent in the cervical region; there is no polyneuropathy,…

October 6, 2015

Gareth John Morgan

“Gareth Morgan is a true world leader in the field of myeloma research.” Read more about Myeloma Institute Director, Dr. Gareth Morgan, in yesterday’s high profile section in the Arkansas Democrat-Gazette newspaper.  

September 18, 2015

How I Treat Myeloma Using Genomic Analysis

Dr. Faith Davies is a professor of medicine and the director of the Phase I Clinical Trials program for both the Myeloma Institute and the Winthrop P. Rockefeller Cancer Institute at the University of Arkansas for Medical Sciences. She is recognized internationally for her focus on innovative targeted molecular therapies and her expertise in the…

September 14, 2015

Understanding Your Multiple Myeloma Genetics and Why You Need to Know

Originally from the UK but now at UAMS, Dr. Gareth Morgan, MD, PhD believes it to be a very valuable test and uses the information that the test provides to alter treatment approaches. He notes: We did significant work comparing the GEP70 to i-FISH, the interface FISH which people out there use as a standard…

August 26, 2015

Genetic Mutation Analysis May Improve Treatment in Multiple Myeloma

Gareth Morgan, M.D., FRCP, FRCPath, Ph.D.

Testing for genetic risk factors may improve myeloma treatments by identifying those at risk for more aggressive disease. This study, published in the Journal of Clinicial Oncology and led by researchers in London, including our own Myeloma Institute Director, Dr. Gareth Morgan, is the first to link genetic mutations in myeloma cells to the chances…

August 13, 2015

New publication

Four genes predict high risk of progression from smoldering to symptomatic multiple myeloma (SWOG S0120)

August 5, 2015

Congratulations to Dr. Frits van Rhee on his newest publication

Frits van Rhee, M.D., Ph.D., MRCP, FRCPath

Congratulations to the international expert, our own Dr. Frits van Rhee, on his newest publication, “A phase 2, open-label, multicenter study of the long-term safety of siltuximab (an anti-interleukin-6 monoclonal antibody) in patients with multicentric Castleman disease”. Be sure to check it out! Read here on Onctotarget

June 9, 2015

Important Lessons Learned from the Measles Virus in Multiple Myeloma

Full MCRI Show: Important Lessons Learned from the Measles Virus in Multiple Myeloma and the Next Step to Advance the Fascinating Viro Therapy with Dr. Frits van Rhee and Dr. Stephen Russell The measles virus grabbed media attention with one patient’s amazing outcome. Dr. Russell and Dr. van Rhee hope to expand those results into…

March 2, 2015

Celgene Gift to UAMS Myeloma Institute for Bart Barlogie Center for Molecular Diagnostics

The Myeloma Institute at the University of Arkansas for Medical Sciences (UAMS) has received a generous gift from Celgene Corporation to benefit patients with multiple myeloma through the creation of The Bart Barlogie Center for Molecular Diagnostics and the establishment of the Celgene Distinguished Endowed Chair in Molecular Therapeutics. “This is an exciting, new collaboration…

Previous page